21-Gene assay as predictor of chemotherapy benefit in HER2-negative breast cancer

פריטים דומים

• Comparison of the Prognostic and Predictive Utilities of the 21-Gene Recurrence Score Assay and Adjuvant! for Women with Node-Negative, ER-Positive Breast Cancer: Results from NSABP B-14 and NSABP B-20
  מאת: Tang, Gong, et al.
  יצא לאור: (2011)
• Association Between the 21-Gene Recurrence Score Assay and Risk of Locoregional Recurrence in Node-Negative, Estrogen Receptor–Positive Breast Cancer: Results From NSABP B-14 and NSABP B-20
  מאת: Mamounas, Eleftherios P., et al.
  יצא לאור: (2010)
• 21-Gene Recurrence Score for prognosis and prediction of taxane benefit after adjuvant chemotherapy plus endocrine therapy: Results from NSABP B-28/NRG Oncology
  מאת: Mamounas, Eleftherios P., et al.
  יצא לאור: (2017)
• Risk of Recurrence and Chemotherapy Benefit for Patients With Node-Negative, Estrogen Receptor–Positive Breast Cancer: Recurrence Score Alone and Integrated With Pathologic and Clinical Factors
  מאת: Tang, Gong, et al.
  יצא לאור: (2011)
• Akt Phosphorylation at Ser473 Predicts Benefit of Paclitaxel Chemotherapy in Node-Positive Breast Cancer
  מאת: Yang, Sherry X., et al.
  יצא לאור: (2010)